Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01631201 · ClinicalTrials.gov registry record · Phase 2

Safety and Efficacy Study of Rifalazil for the Treatment of Chlamydia Trachomatis Infection in Women

A Phase 2 study of Chlamydia Trachomatis Infection, sponsored by ActivBiotics Pharma.

Completed
Registry status
Phase 2
Development phase
82
Enrollment target
5
Study locations

NCT01631201: Completed Phase 2 study of Chlamydia Trachomatis Infection, sponsored by ActivBiotics Pharma.

NCT01631201 is a Phase 2 study of Chlamydia Trachomatis Infection that has completed, run by ActivBiotics Pharma. The registered enrollment target is 82 participants, below the 1,173-participant average among 3 other Chlamydia Trachomatis Infection trials with a reported enrollment target (93% lower). The trial reports 5 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01631201, a Phase 2 study of Chlamydia Trachomatis Infection, has completed, sponsored by ActivBiotics Pharma.

COMPLETED
Registry status
Phase 2
Development phase
82 participants
Enrollment target
5
Study locations

Study Summary

This study will test the safety and effectiveness of an investigational antibiotic drug, rifalazil for the treatment of uncomplicated genital Chlamydia trachomatis infection. This study will examine the effects of 25 milligram of rifalazil compared with azithromycin 1 gram, which will be given as a single dose to women who have genital chlamydial infection.

Primary Outcome

Microbiologic test result will be reported as positive or negative for chlamydia trachomatis.

Interventions

  • DRUG Rifalazil 25 milligram
  • DRUG Azithromycin 1 gram

Study Locations (5)

Alabama

  • Research Site - Birmingham

California

  • Research Site - San Diego

Indiana

  • Research Site - Indianapolis

Nevada

  • Research Site - Las Vegas

Virginia

  • Research Site - Virginia Beach

Trial Details

FieldValue
Enrollment Target 82 participants
Start Date 2012-07
Est. Completion 2013-04
Phase Phase 2
ActivBiotics Pharma

1 total trials

What the finished NCT01631201 record still lists

NCT01631201 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 82 participants, a relatively small participant target, below the 1,173-participant average among 3 other Chlamydia Trachomatis Infection trials with a reported enrollment target (93% lower).

The record links to 1 condition, with Chlamydia Trachomatis Infection appearing as the primary indexed condition, and to 2 interventions - of which Rifalazil 25 milligram is the first listed.

NCT01631201 lists 5 locations in 5 states (Alabama, California, Indiana).

Frequently Asked Questions

What is clinical trial NCT01631201 about?

NCT01631201 is a clinical study titled "Safety and Efficacy Study of Rifalazil for the Treatment of Chlamydia Trachomatis Infection in Women". This study will test the safety and effectiveness of an investigational antibiotic drug, rifalazil for the treatment of uncomplicated genital Chlamydia trachomatis infection. This study will examine the effects of 25 milligram of rifalazil compared with azithromycin 1 gram, which will be given as a ...

What is the current status of trial NCT01631201?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 82 participants. The study started on 2012-07. Estimated completion is 2013-04.

What conditions does trial NCT01631201 study?

This clinical trial studies the following conditions: Chlamydia Trachomatis Infection.

What interventions are being tested in trial NCT01631201?

The interventions under investigation include: Rifalazil 25 milligram (DRUG), Azithromycin 1 gram (DRUG).

Who is sponsoring clinical trial NCT01631201?

This trial is sponsored by ActivBiotics Pharma, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01631201 being conducted?

This trial has 5 study locations across Alabama, California, Indiana, Nevada, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Chlamydia Trachomatis Infection

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03319901 · 82 participants · Phase 1

    Venetoclax and Chemotherapy as Frontline Therapy in Older Patients and Patients With Relapsed/Refractory ALL

  • NCT03493425 · 82 participants · Phase 2

    Chemotherapy Before Surgery and Radiation Therapy or Surgery and Radiation Therapy Alone in Treating Patients With Nasal and Paranasal Sinus Cancer That Can Be Removed by Surgery

  • NCT04105270 · 82 participants · Phase 2

    RMT in Combination With Durvalumab + Chemo in Untreated Adenocarcinoma NSCLC. A Randomized Double Blind Phase II Trial

  • NCT04428658 · 82 participants · NA

    Randomized Trial of Supplemental Synchronous and Asynchronous Telehealth to Improve Glycemic Control for Pediatric Patients With Type 1 Diabetes

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01631201, the US trial registry maintained by the National Library of Medicine. NCT01631201 (small enrollment · multi site footprint · completed) retrieved and formatted by PlainTrial, see methodology.